Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence

Journal of Clinical Oncology

Volumn 14, Issue 12, 1996, Pages 3074-3084

  Rowinsky, E K ^a   Kaufmann, S H ^a   Baker, S D ^a   Grochow, L B ^a   Chen, T L ^a   Peereboom, D ^a   Bowling, M K ^a   Sartorius, S E ^a   Ettinger, D S ^a   Forastiere, A A ^a   Donehower, R C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE DISORDER; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 10544249871     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.12.3074     Document Type: Article

References (35)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
2. Potmesil MP: Camptothecins: From bench research to hospital wards. Cancer Res 54:1431-1439, 1994
3. Chen AY, Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34:191-218, 1994
4. Hsiang Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
5. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19:3295-3300, 1991
6. Pommier Y, Leteurtre F, Fesen MR, et al: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542, 1994
7. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res. 49:5850-5878, 1989
8. Kantajarian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed leukemia. Blood 81:1146-1151, 1993
9. Rowinsky EK, Adjei A, Donehower RC, et al: A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
10. Schiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in extensive stage small cell lung carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 14:2345-2352, 1996
11. Ardizzoni A, Hansen H, Dombernowsky P, et al: Phase II study of topotecan in pretreated small cell lung cancer (sclc). Proc Am Soc Clin Oncol 13:336, 1994 (abstr)
12. Kudelka A, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
13. Armstrong D, Rowinsky E, Donehower RC, et al: Phase II study of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275, 1995 (abstr)
14. Robert F, Wheeler RH, Molthrop DC, et al: Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 13:281, 1994 (abstr)
15. Eisenhauer EA, Wainman G, Boos G, et al: Phase II trials of topotecan in patients (pts) with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 13:175, 1994 (abstr)
16. Cheng M-F, Chatterjee S, Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269-279, 1994
17. Johnson RK, McCabe FL, Yu Y: Combination regimens with topotecan in animal tumor models. Ann Oncol 3:85, 1992 (abstr)
18. Chou T-C, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinom cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
19. Drewinko B, Green C, Loo TL: Combination chemotherapy in vitro. III. BCNU. Cancer Treat Rep 63:373-375, 1979
20. Drewinko B, Loo TL, Green C: Combination chemotherapy in vitro with cis-dichlorodiammineplatinum (II). Cancer Treat Rep 60:1619-1625, 1976
21. Kano Y, Suzuki K, Akutau M, et al: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50:604-610, 1992
22. Katz EJ, Vick JS, Kling KM, et al: Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 26:724-727, 1990
23. Kim R, Hirabayashi N, Nishiyama M, et al: Experimental studies on biochemical modulation targeting topoisomerase I and topoisomerase II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992
24. Kaufmann SH, Peereboom D, Buckwalter CA, et al: Cytotoxic interactions between topotecan and diverse anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741, 1996
25. Rowinsky E, Grochow L, Hendricks C, et al: Phase I and pharmacologic study of topotecan (SK&F 104864): A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
26. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
27. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan. Drug Met Dispos 20:706-712, 1992
28. Rowinsky EK, Grochow LB, Sartorius SE, et al: A phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor. J Clin Oncol 14:2224-2235, 1996
29. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide, University of Southern California. Los Angeles, CA, Biomedical Simulations Resource, 1990.
30. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55, 1984
31. Bramson J, Prevost J, Malapetsa A, et al: Poly(ADP-ribose) polymerase can bind melphalan damaged DNA. Cancer Res 53:5370-5373, 1993
32. Burkle A, Chen G, Kupper JH, et al: Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 14:559-561, 1993
33. Mattem MR, Mong S-M, Bartus HF, et al: Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47:1793-1798, 1987
34. Chatterjee S, Cheng MR, Trivedi D, et al: A camptothecin hypersensitivity in poly(ADP-Ribose) polymerase-deficient cell lines. Cancer Commun 1:389-394, 1989
35. Miller AA, Hargis JB, Lilenbaum R, et al: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 12:2743-2750, 1994